eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) major shareholder Presidio Management Group X. Ll sold 4,000 shares of the stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $2.54, for a total transaction of $10,160.00. Following the completion of the transaction, the insider now owns 140,137 shares in the company, valued at $355,947.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of eFFECTOR Therapeutics stock opened at $2.25 on Thursday. eFFECTOR Therapeutics, Inc. has a twelve month low of $2.03 and a twelve month high of $40.42. The company has a debt-to-equity ratio of 1.09, a quick ratio of 13.30 and a current ratio of 13.30. The business has a 50-day moving average price of $3.76 and a 200-day moving average price of $5.94.
eFFECTOR Therapeutics (NASDAQ:EFTR – Get Rating) last released its quarterly earnings data on Wednesday, March 16th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.69. The firm had revenue of $0.31 million during the quarter. Sell-side analysts expect that eFFECTOR Therapeutics, Inc. will post -1.02 EPS for the current year.
Several large investors have recently modified their holdings of EFTR. SR One Capital Management LP purchased a new stake in shares of eFFECTOR Therapeutics during the 4th quarter valued at about $56,487,000. Abingworth LLP purchased a new stake in eFFECTOR Therapeutics during the third quarter valued at approximately $67,027,000. Sectoral Asset Management Inc bought a new stake in shares of eFFECTOR Therapeutics in the 3rd quarter valued at approximately $40,503,000. OUP Management Co. LLC bought a new stake in shares of eFFECTOR Therapeutics in the 4th quarter valued at approximately $8,493,000. Finally, Parallel Advisors LLC bought a new position in shares of eFFECTOR Therapeutics during the 1st quarter valued at approximately $2,744,000. 51.71% of the stock is owned by institutional investors and hedge funds.
About eFFECTOR Therapeutics (Get Rating)
eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on eFFECTOR Therapeutics (EFTR)
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.